Physician profile
James Rodio
NPI 1275614513
$4,369.98
in general payments reported to CMS, 2019-2025
22 companies · $484 in 2025
The $484 reported for 2025 was more than what a typical Psychiatry provider received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $536 · 2020: $188 · 2021: $517 · 2022: $687 · 2023: $829 · 2024: $1,130 · 2025: $484.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,334 · Education: $109.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,333.80 |
| Education | $108.76 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $669.51 | 2019-2025 | Abilify Asimtufii, Abilify Maintena, Rexulti |
| Teva Pharmaceuticals USA, INC. | $637.78 | 2019-2025 | Austedo Xr, Uzedy |
| Abbvie INC. | $606.83 | 2021-2025 | Vraylar |
| Lundbeck LLC | $413.87 | 2019-2024 | Rexulti, Abilify Maintena |
| Neurocrine Biosciences, INC. | $358.13 | 2022-2025 | Ingrezza |
| E.R. Squibb & Sons, L.L.C. | $263.95 | 2024-2025 | Cobenfy |
| Indivior INC. | $263.31 | 2019-2025 | Sublocade, Perseris |
| Vanda Pharmaceuticals INC. | $215.12 | 2019-2024 | Hetlioz, Fanapt |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $196.89 | 2021-2025 | Caplyta |
| Corium, LLC | $145.02 | 2022-2024 | Azstarys |
| Janssen Pharmaceuticals, INC | $113.05 | 2019-2024 | Invega Sustenna, Spravato, Invega Trinza |
| Noven Therapeutics, LLC | $89.21 | 2021-2024 | Xelstrym, Secuado |
| Alkermes, INC. | $83.80 | 2021-2024 | Aristada, Lybalvi |
| Takeda Pharmaceuticals U.S.A., INC. | $75.09 | 2021-2024 | Trintellix, Vyvanse |
| Axsome Therapeutics, INC. | $66.42 | 2023-2024 | Auvelity |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Tempus Ai, INC | $39.92 | 2024 | |
| Almatica Pharma LLC | $39.00 | 2021-2024 | Loreev Xr |
| Ironshore Pharmaceuticals INC. | $29.51 | 2024 | |
| Bausch Health US, LLC | $26.14 | 2022 | |
| Neuronetics, INC. | $13.53 | 2023 | Neurostar Tms Therapy System |
| Sunovion Pharmaceuticals INC. | $12.10 | 2019 | |
| Supernus Pharmaceuticals, INC. | $11.80 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Rodio listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.